ODEPHARMA
ActiveSummary
ODEPHARMA has been active since 1990 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €115,621 and a net result of €69,636. Equity is growing by about 61% per year across the filed financial years. Its solvency ranks better than 59% of 12,661 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Directors
Board 1
Permanent representatives 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Lindammer |
|
| An LOUWAGIE |
|
| Kristiaan TRYPSTEEN |
|
| PAN PROJECT |
|
Owners and capital
Owners
1 ownerChain of control
- PAN PROJECT
- ODEPHARMA
Highest known parent: PAN PROJECT. The sources do not say who stands above it.
Owners 1
- PAN PROJECTparent99.52%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 27-12-2024 Capital stated in the deed · €62,000 · 1,250 shares